89Zr-Bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment

Journal of Nuclear Medicine

Volumn 56, Issue 1, 2015, Pages 63-69

  Oosting, Sjoukje F ^a   Brouwers, Adrienne H ^a   Van Es, Suzanne C ^a   Nagengast, Wouter B ^a   Munnink, Thijs H Oude ^a   Lub De Hooge, Marjolijn N ^a   Hollema, Harry ^a   De Jong, Johan R ^a   De Jong, Igle J ^a   De Haas, Sanne ^b   Scherer, Stefan J ^c   Sluiter, Wim J ^a   Dierckx, Rudi A ^a   Bongaerts, Alfons H H ^a   Gietema, Jourik A ^a   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c GENENTECH INC   (United States)

Author keywords

Bevacizumab; Molecular imaging; Positron emission tomography; Renal cell carcinoma; Sunitinib

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; BEVACIZUMAB ZR 89; SUNITINIB; TRACER; UNCLASSIFIED DRUG; VASCULOTROPIN A; ZIRCONIUM DERIVATIVE; 89ZR-BEVACIZUMAB; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PYRROLE DERIVATIVE;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RESISTANCE; CLINICAL ARTICLE; DRUG EFFECT; DRUG TUMOR LEVEL; HUMAN; KIDNEY CARCINOMA; METASTASIS POTENTIAL; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; AGED; BLOOD; CARCINOMA, RENAL CELL; DIAGNOSTIC USE; FEMALE; KIDNEY NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL TRANSPORT; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RADIOACTIVE TRACERS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84920445585     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.144840     Document Type: Article

References (29)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
2. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial. Lancet. 2007; 370: 2103-2111.
3. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-1068.
4. Páez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15: 220-231.
5. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15: 232-239.
6. Hegde PS, Jubb AM, Chen D, et al. Predictive impact of circulating vascular endothelial growth factor in 4 phase III trials evaluating bevacizumab. Clin Cancer Res. 2013; 19: 929-937.
7. Miles DW, de Haas SL, Dirix LY, et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for Her2-negative metastatic breast cancer. Br J Cancer. 2013; 108: 1052-1060.
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009; 27: 3312-3318.
9. Harmon CS, DePrimo SE, Figlin RA, et al. Circulating proteins as potential biomarkers of sunitinib and interferon-a efficacy in treatment-naïve patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2014; 73: 151-161.
10. Bais C, Rabe C, Wild N, et al. Comprehensive reassessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in 13 pivotal trials (seven indications) [abstract]. J Clin Oncol. 2014; 32: 5S.
11. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993; 4: 1317-1326.
12. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in an ovarian tumor xenograft. J Nucl Med. 2007; 48: 1313-1319.
13. 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med. 2013; 54: 1014-1018.
14. 89Zrbevacizumab tumor uptake in patients with neuroendocrine tumors. J Nucl Med. 2014; 55: 1087-1092.
15. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003; 2: 131-137.
16. 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010; 87: 586-592.
17. 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med. 2008; 49: 1066-1074.
18. 111In-bevacizumab in stage III/IV melanoma patients. Eur J Cancer. 2011; 47: 1595-1602.
19. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883-892.
20. Horswell S, Matthews N, Swanton C. Cancer heterogeneity and "The struggle for existence": diagnostic and analytical challenges. Cancer Lett. 2013; 340: 220-226.
21. 11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain. Neoplasia. 2013; 15: 1347-1353.
22. DePrimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007; 5: 32-42.
23. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA. 2007; 104: 17069-17074.
24. Pastuskovas CV, Mundo EE, Williams SP, et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther. 2012; 11: 752-762.
25. Arjaans M, Oude Munnink TH, Oosting SF, et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res. 2013; 73: 3347-3355.
26. Van der Veldt AA, Lubberink M, Bahce I, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell. 2012; 21: 82-91.
27. Nagengast WB, Lub-de Hooge MN, Oosting SF, et al. VEGF-PET imaging is a non-invasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res. 2011; 71: 143-153.
28. Griffioen AW, Mans LA, de Graaf AM, et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res. 2012; 18: 3961-3971.
29. 111In-bevacizumab imaging of renal cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. J Nucl Med. 2010; 51: 1707-1715.